Compare Mercadolibre Inc (MELI) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs Pfizer Inc — how do they compare? Mercadolibre Inc trades at $1,854.25 (market cap $94.94B), while Pfizer Inc trades at $27.78 (market cap $159.59B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays a 6.14% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mercadolibre Inc for 117 Days and Pfizer Inc for 158 Days on average.
| MELI | PFE | |
|---|---|---|
Market Cap | $94.94B | $159.59B |
Volume | 428,337 | 30,937,010 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.36K | $29.02 |
52-Week Low | $1.55K | $23.67 |
Typical Hold Time | 117 Days | 158 Days |
Enterprise Value | $102.59B | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,856.66, down slightly by 0.07% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported $28.89 billion in revenue for 2025, with net income of $2.00 billion, though profit margins have softened from 9.19% in 2024 to 6.91%. Recent news highlights expansion in Brazil, including one-hour delivery and pharmacy growth, while the fintech segment's credit portfolio surged 75% to $16.4 billion in Q2 2026.
The stock presents a growth opportunity with robust revenue expansion and dominant market position in Latin American e-commerce and fintech, but faces risks from macroeconomic pressures in key markets like Argentina and elevated valuation multiples. Analyst consensus is strongly bullish with a $2,170 price target, suggesting potential upside, though investors should weigh margin compression against ecosystem strength.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
